In vitro activity of new quinolones against Clostridium difficile | Zendy

Roberto Alonso | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In vitro activity of new quinolones against Clostridium difficile

Author(s) -

Roberto Alonso

Publication year - 2001

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/47.2.195

Subject(s) - trovafloxacin , ofloxacin , ciprofloxacin , levofloxacin , clostridium difficile , microbiology and biotechnology , medicine , antibacterial agent , pharmacology , antibiotics , biology

We evaluated the in vitro activities of ofloxacin, levofloxacin, grepafloxacin, trovafloxacin and ciprofloxacin against Clostridium difficile. The MIC(90) was 128 mg/L for ofloxacin and levofloxacin, 64 mg/L for ciprofloxacin, 16 mg/L for grepafloxacin and 8 mg/L for trovafloxacin. Thirty per cent of isolates were resistant to trovafloxacin, and rates of resistance to ofloxacin, levofloxacin, grepafloxacin and ciprofloxacin were considerably higher. None of the antimicrobials studied would be a reliable therapeutic option against C. difficile. Whether some of the new fluoroquinolones can induce C. difficile-associated diarrhoea remains to be answered.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research